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ABSTRACT
In the past decades, RNA molecules have emerged
as important players in numerous cellular pro-
cesses. To understand these processes at the mo-
lecular and atomic level, large amounts of
homogeneous RNA are required for structural,
biochemical and pharmacological investigations.
Such RNAs are generally obtained from laborious
and costly in vitro transcriptions or chemical syn-
thesis. In 2007, a recombinant RNA technology has
been described for the constitutive production of
large amounts of recombinant RNA in Escherichia
coli using a tRNA-scaffold approach. We demon-
strate a general applicable extension to the
described approach by introducing the following im-
provements: (i) enhanced transcription of large
recombinant RNAs by T7 RNA polymerase (high
transcription rates, versatile), (ii) efficient and facile
excision of the RNA of interest from the tRNA-
scaffold by dual cis-acting hammerhead ribozyme
mediated cleavage and (iii) rapid purification of the
RNA of interest employing anion-exchange chroma-
tography or affinity chromatography followed by
denaturing polyacrylamide gel electrophoresis.
These improvements in the existing method pave
the tRNA-scaffold approach further such that any
(non-)structured product RNA of a defined length
can cost-efficiently be obtained in (multi-)milligram
quantities without in vitro enzymatic manipulations.
INTRODUCTION
Systematic studies of the structure and function of RNA
molecules, ligand screening in pharmaceutical drug devel-
opment and several other biophysical techniques usually
require milligram quantities of homogeneous and pure
RNA. Such studies applied to proteins greatly beneﬁted
from the development of various bacterial and eukaryotic
recombinant expression systems. In contrast to proteins,
such recombinant systems for RNA are not readily avail-
able, and RNA has therefore mostly been produced by
in vitro transcription from DNA templates (1) and via
chemical synthesis (2). Both production methods are
costly, laborious and have their drawbacks with respect
to sequence requirements, variations in yield, non-
templated nucleotide additions and/or the maximum
length of the oligonucleotide. Recombinant RNA synthesis
in bacteria could be a suitable alternative to overcome these
problems; however, the production of homogeneous RNA
in vivo has been impeded by host nuclease degradation and
the inability to purify the RNA of interest from the cellular
RNAs.Until recently, the only recombinantRNAs success-
fully produced were 5S ribosomal RNA (5S rRNA) (3),
transfer RNAs (tRNAs) (4–7) and (derivatives of) natural
RNAs that occur as stable molecules (8–10). This has been
possible because these RNAs are recognized by cellular
machinery, and the primary transcript is precisely pro-
cessed, post-transcriptionally modiﬁed and prevented
from 30-polyadenylation that triggers RNA degradation
(11–13). The ability of these RNAs to escape nuclease deg-
radation has been adapted by Ponchon and Dardel to
produce recombinant RNA by substituting the anticodon
stem-loop of a tRNA for a structured RNA molecule, a
strategy which they called the tRNA-scaffold approach
(14–16). The tRNA-scaffold in the chimera possesses the
same properties as a regular tRNA and is being recognized
and processed by the cellular machinery in a similar
fashion. The tRNA-chimers are protected from breakdown
by host nucleases and accumulate to copious amounts
inside the bacterial cells. Although this approach yields
large amounts of pure and homogeneous recombinant
RNA, the RNA fragment of interest is covalently
attached to the tRNA-scaffold. To release this RNA,
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Ponchon and Dardel employed in vitro RNase H cleavage
directed by two DNA oligonucleotides complementary to
the invariable part of the tRNA-scaffold. The released
RNA of interest was puriﬁed from the DNA oligonucleo-
tides and the remainder of the tRNA-scaffold by anion-
exchange chromatography under denaturing conditions.
More recently, a strategy similar to the tRNA-scaffold
approach was demonstrated by Liu et al. (17) who
inserted a 71-nt product RNA in place of helix III-loop C
segment of the 5S ribosomal RNA of Vibrio proteoliticus
and produced this recombinant RNA constitutively in
Escherichia coli. In this approach, excision of the product
RNA from the 5S rRNA scaffold is mediated via
biotinylated DNAzyme cleavage.
In this contribution, a general applicable improvement
of the existing tRNA-scaffold approach is described that
allows for the production of large amounts of homoge-
neous product RNAs that are released from the protective
tRNA-scaffold without the requirement of any in vitro en-
zymatic manipulation or input of (modiﬁed) DNA oligo-
nucleotides. To accomplish this, the recombinant RNA
molecule consists of the human tRNAlys-scaffold with a
Sephadex aptamer fused to the anticodon stem, similar as
has been demonstrated by Ponchon and Dardel. This
construct is used to insert various RNA cassettes on top
of the Sephadex aptamer (Figure 1A and Supplementary
Figure S1) each consisting of the RNA of interest (product
RNA) ﬂanked with cis-acting hammerhead (HH) ribo-
zymes. The DNA sequence coding for the recombinant
RNA molecule is inserted downstream the T7 promotor
sequence in pET23b (Novagen), a vector commonly used
for recombinant protein expression (18,19), allowing
transcription of RNA in E. coli BL21 (DE3) to be
initiated upon the addition of isopropyl b-D-
1-thiogalactopyranoside (IPTG). The recombinant RNA
is puriﬁed from the host RNAs by anion-exchange chro-
matography and/or by afﬁnity chromatography using
Sephadex G-200. The product RNA excised from the
scaffold after HH ribozyme cleavage is separated from
the scaffold moiety using preparative denaturing poly-
acrylamide gel electrophoresis (PAGE). The general ap-
plicability of this method is demonstrated by the
production of a variety of RNA molecules (displayed in
Figure 1B). We also show that mutants of the product
RNAs can rapidly be obtained by using site-directed mu-
tagenesis (20) and fusion-PCR (21), demonstrated by the
production of several mutants of the Duck Hepatitis B
Virus epsilon encapsidation signal RNA (22) (displayed
in Figure 1C). Finally, we show that stable isotope
labeling for NMR structural analysis is easily and
cost-efﬁciently achieved by the example of the production
on 15N-substituted minimal medium of three different
sequences of the Duck HBVe RNA sequence.
MATERIALS AND METHODS
Vector construction
Prior to vector construction, the folds of the full-recom-
binant RNAs were predicted using the program Mfold
(23). The desired folds of the RNAs (Figure 1A and
Supplementary Figure S1) were obtained by varying the
length of the arms and the nucleotide composition in the
four-way junction region (Figure 1A and Supplementary
Figure S1, blue residues) until the desired structures were
predicted to be more stable than the predicted alternative
structures. The DNA sequence coding for the tRNAlys-
scaffold with sephadex aptamer containing the Human
HBVe RNA ﬂanked with cis-acting HH ribozymes
(Figure 1A) was purchased from Baseclear (Leiden, The
Netherlands). This DNA template was cloned into the
XbaI+XhoI restriction sites of vector pET23b
(Novagen) (Figure 2) thereby retaining the purine-rich
DNA sequence between the T7 RNA polymerase
promoter sequence and the XbaI site to ensure efﬁcient
initiation of RNA transcription. This vector was subse-
quently used as a shuttle vector for subcloning various
cassettes coding for HH ribozyme ﬂanked product
RNAs, listed in the upper section of Supplementary
Table S3 (see Supplementary Figure S1 for all secondary
structure representation of the full-recombinant RNAs).
The cloning sites were SmaI (50) and SacII (30), located just
above the Sephadex aptamer (Figure 1A, brown residues).
This speciﬁc combination of restriction enzymes ensured
that the stem above the Sephadex aptamer in the RNA
transcript formed correctly and that the insert RNAs
would not interfere with the fold of the protective
tRNAlys-scaffold.
Site-directed mutations were introduced into the
pET23b-vector containing the DNA sequence for the
Duck HBVe RNA (or a mutant hereof) to obtain the
desired mutant RNAs of the Duck HBVe RNA (displayed
in Figure 1C) as described (20,21) (See Supplementary
Tables S1 and S2 for used oligonucleotides and
Supplementary Figure S2 for a more detailed description).
The DNA sequence of each construct was veriﬁed
(Baseclear) prior to recombinant RNA productions.
RNA production
Freshly transformed E. coli BL21 (DE3) cells or from
glycerol stock were plated on LB-agar containing 50 mg/
ml ampicillin and grown overnight at 37C. For checking
the level of recombinant RNA production, a single colony
was picked and cultivated in 5ml of TB medium or LB
medium (24) containing 50mg/ml ampicillin (TB-amp50/
LB-amp50) at 37C, 250 rpm. At OD600nm 0.6–0.8,
IPTG was added to a concentration of 1mM, and culti-
vation was continued for 3 h. Every hour post-induction,
the cells from 1ml of culture were pelleted and resus-
pended in 100 ml of 10mM Tris-HCl (pH 7.4) + 10mM
magnesium acetate (buffer L). The suspension was ex-
tracted with 100 ml of phenol saturated with buffer L,
and the aqueous phase was ethanol precipitated by
adding 0.1 volume of 3M sodium acetate (pH 5.2) and 3
volumes of ethanol. The pellet was dissolved in 20 ml of
Milli-Q water and mixed with 20 ml of 50mM EDTA in
formamide containing 0.02% bromophenol blue and
0.02% xylene cyanol (2 LB). The RNA was analyzed
by electrophoresis on an analytical 8% polyacrylamide
gel in 1 TBE containing 8M urea. For large-scale
cultures of unlabeled RNA, 30ml of overnight preculture
e102 Nucleic Acids Research, 2012, Vol. 40, No. 13 PAGE 2 OF 12
Figure 1. Secondary structure representations of the recombinant (product) RNAs. (A) From left to right, the constructs for the Human HBVe
RNA—the long construct for the B. subtilis guanine riboswitch aptamer RNA and the short construct for the B. subtilis guanine riboswitch aptamer
RNA—are displayed. The tRNAlys-scaffold is shown in black (modiﬁed nucleotides in purple), the Sephadex aptamer in red, the HH ribozymes
ﬂanking the RNA of interest are in orange and the two variable arms base pairing with the ends of the RNA of interest in blue. The brown
nucleotides are the restriction sites for subcloning. The bonds between the nucleotides that are cleaved by the HH ribozymes are indicated by arrows.
The 50-end and 30-end of the tRNAlys-scaffold are depicted as matured termini. See Supplementary Figure S1 for representations of the additional
produced full-recombinant RNAs. (B) Different types of recombinant product RNAs, from left to right: Human HBVe RNA (15,63–65), B. subtilis
guanine riboswitch aptamer RNA (66), HIV-1 TAR (67) RNA and Duck HBVe RNA (22,35,68). (C) Produced mutants of the Duck HBVe RNA.
The introduced mutations with respect to the Duck HBVe RNA are shown in red. The presented secondary structures of the mutants of Duck HBVe
RNA are for visual clariﬁcation of the location of the introduced mutations and are, except for Duck HBVe-mutL4, not in accordance with the
predicted secondary structures obtained with Mfold. The indicated yields are from 1 l cultures employing anion-exchange chromatography except for
those indicated with a single red asterisk, which were puriﬁed with Sephadex G-200 afﬁnity. Yields indicated with two red asterisks are obtained from
1 l of 15N-labeled minimal media, n.p., not produced on liter scale. See Supplementary Table S3 for the nucleotide sequence of all product RNAs.
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was added to 1 l of TB-amp50 or LB-amp50 in a bafﬂed 2 l
Erlenmeyer. 15N-labeled RNA was produced by inocula-
tion of 1 l minimal medium [125 mM potassium phosphate
buffer (pH 7.2), 35mM Na2SO4, 27.5mM
15NH4Cl,
15mM D-(+)-glucose, 1mM MgSO4 and 50 mg/ml ampi-
cillin] with 100ml of overnight preculture grown on the
same minimal medium. Cells were cultivated and induced
as described for the 5ml cultures.
RNA puriﬁcation using anion-exchange chromatography
Cells from 1 l of culture were pelleted and resuspended in
40ml of buffer L. The RNA was extracted from the cells
by the addition of 20ml of phenol saturated in buffer L
and gentle agitation for 30min at room temperature. The
suspension was centrifuged at 7500 g in a JA-14 rotor
(Beckman) at 4C for 10min; the aqueous phase was
pipetted off, and the organic layer was re-extracted with
another 20ml of buffer L. The aqueous phases were
pooled and dialyzed overnight at 4C against 2.5 l of
20mM Tris-HCl (pH 8.1) + 0.25mM EDTA in a 6–
8 kDa MWCO dialysis tubing (Spectra), refreshing the
dialysis buffer once. The dialyzed RNA was diluted
4-fold with 20mM Tris-HCl (pH8.1), and MgCl2 was
added to 10mM. This mixture was incubated at 37
C
for 1 h to cleave the residual intact HH ribozymes. Any
formed precipitate was removed by centrifugation at
20 000 g in a JA-14 rotor at 4C for 30min, and the
RNA was loaded with 5ml/min onto a ResourceQ 6ml
column (GE Healthcare) equilibrated in 25 mM Tris-HCl
(pH 8.1) + 1mM EDTA (buffer C) connected to an
A˚KTA basic (GE Healthcare). Bound RNA was eluted
by applying a segmented linear gradient (Supplementary
Table S4) to 1.5M NaCl in buffer C. Eluate that showed
UV absorbance was collected in fractions of 5ml. Twenty
microliters of each fraction was mixed with 20 ml 2 LB
and checked on 8% PAGE. The fractions containing
recombinant RNA were pooled, concentrated by ethanol
precipitation and puriﬁed as described under preparative
denaturing PAGE.
RNA puriﬁcation using Sephadex G-200 afﬁnity
chromatography
Cells from 1 l of culture were pelleted and resuspended in
50ml of binding buffer [buffer SB; 50mM potassium
phosphate buffer (pH 7.5) + 10mM MgCl2+100mM
NaCl] containing 200 mg/ml lysozyme. The suspension
was sonicated four times during 30 s with intervals of
2min on ice. The cellular debris was removed by centrifu-
gation at 30 000 g in a JA-20 rotor (Beckman) for 30min
at 4C. One hundred milliliters of Sephadex G-200 swollen
in buffer SB was added to the supernatant, and the RNA
was allowed to bind at 4C for 2 h under gentle agitation.
The slurry was poured into a glass column (ø2.5 cm) and
allowed to settle. The ﬂow-through was collected, and the
column was washed with portions of 15ml buffer SB
until the RNA concentration of the wash dropped to
100 ng/ml, which was determined with UV absorbance
using a Nanodrop 1000 spectrophotometer (Isogen). The
bound RNA was eluted with buffer SB containing 4M
urea and collected in fractions of 10ml. Recombinant
RNA containing fractions were pooled and dialyzed
against 2.5 l of 20mM Tris-HCl (pH 8.1) + 0.25mM
EDTA in a 6–8 kD MWCO dialysis tubing (Spectra) at
4C, refreshing the dialysis buffer once. MgCl2 was added
to the dialyzed RNA to 10mM, and the residual intact
HH ribozymes were cleaved by incubation at 37C for 1 h.
The RNA was concentrated by ethanol precipitation and
puriﬁed using denaturing PAGE as described below.
Preparative denaturing PAGE and NMR spectroscopy
Ethanol precipitated RNA was dissolved with Milli-Q
water to 2.5ml; the RNA concentration was determined
by UV spectroscopy and mixed with 2.5ml of 2 LB. The
sample was boiled at 95C for 10min and puriﬁed over
preparative denaturing 8% polyacrylamide gel (19:1) in
1 TBE containing 8M urea and 5mM EDTA. Per pre-
parative gel (435 380 3mm) a maximum of 20mg of
column puriﬁed RNA was loaded and electrophorized for
16 h (overnight) at 300V. The band of the product RNA
was excised from the gel under UV shadowing on a TLC
Silica gel 60 F254 plate (Merck) using a 254-nm wavelength
UV lamp. The RNA was subsequently electro eluted from
the gel bands at 180V using an Elutrap device (Schleicher
& Schuell) and subsequently ethanol precipitated. The
RNAs were further puriﬁed by extensive dialysis in a
centricon YM-10 device (Amicon) as described earlier
(25) and lyophilized. For NMR structural analysis, un-
labeled and 15N-labeled Duck HBVe RNA, Duck
HBVe-mutS1a RNA and Duck HBVe-mutL4 RNA were
reconstituted in 300 ml of NMR buffer [10 mM sodium
phosphate (pH 6.7), 10 mM EDTA and 7% D2O] to
obtain RNA concentrations in the range of 0.3–0.6mM.
The samples were heated at 95C for 2min, snap cooled
on ice-water and transferred to a Shigemi NMR tube.
NMR data were acquired at 800MHz 1H frequency at
15C on a Varian Unity Inova spectrometer equipped
with a cryo-cooled probe. The 1H, 15N-HMQC-spectra
Figure 2. Schematic of the used vector for recombinant RNA synthe-
sis. The cloning site for the insertion of the various DNA sequences is
ﬂanked with a SmaI and a SacII site for directed cloning. The color
coding of the blocks correspond with the sequence colors in the
full-recombinant RNA transcript (Figure 1A). The 50-transcription ini-
tiation region (50-TIR) directly after the T7 promotor sequence ensures
efﬁcient transcription initiation by T7 RNA polymerase. Transcription
is terminated by the presence of the rrnC terminator sequence at the
30-end of the coding DNA sequence.
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were recorded with 4096 (t2) 200 (t1) points for a spectral
width of 20 kHz (1H) and 1.5 kHz (15N) [see e.g. (26,27)].
A 800MHz (1H, 1H) NOESY spectrum of the unlabeled
Duck HBVe-mutS1a RNA was recorded with 512 (t1) 
4096 (t2) points for a spectral width of 17 kHz (t1) by
20 kHz (t2) and a mixing time of 300ms [see e.g.
(26,27)]. Spectra were processed with NMRpipe (28),
and resonances were assigned using the program
SPARKY (T.D. Goddard and D.G. Kneller, University
of San Francisco).
RESULTS
Principle of the method
Our approach for the synthesis of recombinant RNA is
based on the tRNA-scaffold strategy that was ﬁrst
described by Ponchon and Dardel (14–16). Different
from their method, our RNA is not constitutively
produced in the E. coli cells, but transcription is initiated
during growth at an OD600nm of 0.6–0.8 by the addition of
IPTG, comparable with modern recombinant protein syn-
thesis techniques. Furthermore, the termini of the product
RNA are ﬂanked with cis-acting hammerhead (HH) ribo-
zymes (Figure 1A), leading to an efﬁcient excision of the
product RNA from the scaffold after the addition of
MgCl2 to the recombinant RNA and a 1-h incubation at
37C. This facile ribozyme-mediated cleavage circumvents
the requirement of enzymatic in vitro RNase H treatment
to release the product RNA from the tRNA-scaffold.
After ribozyme cleavage, the global structure of the full
RNA is retained through 10–15 base pairing interactions
of the 50-region and 30-region of the product RNA with
the arms of the scaffold. This allows for the separation of
the large recombinant RNA from the smaller tRNAs, 5S
rRNA and small RNA fragments by anion-exchange puri-
ﬁcation or alternatively, since the recombinant RNA mol-
ecules are equipped with a Sephadex aptamer (29,30), by
afﬁnity chromatography using Sephadex G-200. Finally,
the product RNA is separated from the tRNA-scaffold on
preparative denaturing PAGE. The difference in sequence
length between the product RNA and the two scaffold
moieties allows for efﬁcient and clean excision of the
product RNA band from the gel. The product RNA is
further puriﬁed employing electro-elution and extensive
ultra-ﬁltration dialysis. Supplementary Table S4 gives an
overview of the expected timing for each of the employed
puriﬁcation steps and the expected total production time
of an NMR sample of RNA.
The feasibility of the method is demonstrated by the
production of several RNA molecules (Figure 1 and
Supplementary Figure S1), and NMR structural analysis
is demonstrated on unlabeled and 15N-labeled Duck
HBVe RNA and Duck HBVe-mutS1a RNA.
Construct design
The various RNA cassettes that are placed on top of the
Sephadex aptamer are designed in such a way that they do
not disturb the predicted secondary structure of the pro-
tective tRNA-scaffold (Figure 1A and Supplementary
Figure S1). The SmaI (50) and SacII (30) restriction sites
located in the stem above the Sephadex aptamer are suc-
cessfully used for cloning the insert cassettes in the correct
orientation and retaining the desired base pairings in this
stem for stability (Figure 1, brown residues). Each RNA
cassette consists of three basic elements, namely (i) the
product RNA (green) ﬂanked with (ii) cis-acting hammer-
head ribozymes (orange) and (iii) two arms (blue) that
base pair with the 10–15 terminal nucleotides of the
product RNA facilitating efﬁcient ribozyme cleavage
and downstream puriﬁcation. The desired fold of the
recombinant RNA molecules is complex, and therefore
representations of the predicted secondary structure were
generated with in silico folding simulations using the
Mfold web server (23). To obtain the desired fold pre-
dicted more stable than alternate structures, the length
of the arms and the nucleotide composition of the
junction regions (only in the blue residues) were altered.
RNA production
All unlabeled recombinant RNA transcriptions have been
carried out in either TB medium or LB medium. The pro-
duction yields differed not signiﬁcantly on the type of
employed growth medium. Prior to large-scale cultures,
5ml cultures were grown to check RNA transcription
levels. During 3 h post-induction, 1ml samples were
taken from the culture every hour and the RNA content
was checked on 8% denaturing PAGE. Figure 3A shows
an example of a time-course experiment for the produc-
tion of the Human HBVe RNA (HHBVe). It is observed
that recombinant RNA (indicated with red arrows) stably
accumulates after induction. Generally, the plateau of
RNA accumulation was reached 3 h post-induction.
Incubations extended up to 6 h showed no difference on
the amount of produced RNA, but overnight incubation
resulted in degradation of the majority of the recombinant
RNA (results not shown). The band of the full (i.e.
without HH ribozymes cleaved) recombinant RNA is
indicated with two arrows, of which the upper band
contains the vector borne 50 transcription initiation
region (50-TIR) RNA still attached to the tRNA-
scaffold. The presence of this incompletely processed
scaffold moiety depends on the produced RNA and is
not always observed. The band pattern of the recombinant
RNA shows that the HH ribozymes are already cleaved to
some extent inside the bacterial cells during the time of
production. The bands containing the majority of recom-
binant RNA are accredited to ‘Scaffold + Product  1
HH cleaved off’ and to ‘Scaffold moiety’ (it is here not
clear which HH has been cleaved and which side of the
scaffold moiety is seen). The band indicated with ‘product
RNA’ (i.e. the released RNA after dual HH cleavage) is
located below the tRNAs. After dialysis of the aqueous
phase, the residual intact HH ribozymes were readily
cleaved after 4-fold dilution of the RNA in fresh dialysis
buffer supplemented with 10mM MgCl2 and 1-h incuba-
tion at 37C (Figure 3B, HHBVe-RNA). The HH ribo-
zymes cleaved to completion as can be observed from
the disappearance of the bands accredited to ‘Full RNA’
and ‘Scaffold+Product-one HH cleaved’ from Figure 3a
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(red circled) and only the bands of the scaffold RNA (S)
and product RNA (P) present as recombinant RNA.
For all designed RNA constructs and/or mutants,
similar band patterns were obtained (Figure 3C). As can
be observed from Figure 3C, the production efﬁciencies
are different for each construct. For instance, the con-
structs for Duck HBVe-mutL4 RNA and Duck
HBVe-mutF1 RNA produce better than the long con-
struct for the guanine riboswitch aptamer (GRA) and
the construct for the HIV-1 TAR RNA. We generally
obtained yields in the range of 10–30mg of unlabeled
full-recombinant RNA per liter (corresponding to
2–4.5mg of puriﬁed product RNA). The yields of full-
recombinant RNA and puriﬁed product RNA obtained
from minimal media cultures were somewhat lower,
7.515 and 1.5–2.5mg/l, respectively.
RNA puriﬁcation
After extraction of the bacterial cells using phenol
saturated with 10mM Tris-HCl (pH 7.5) containing
10mM magnesium acetate, the majority of the large
23S/16S ribosomal RNAs, proteins and the chromosomal
DNA precipitate or are located in the organic phase,
whereas the recombinant RNA (and also tRNAs, 5S
rRNA and small RNAs) are located in the aqueous
phase. The implementation of a re-extraction step of the
organic phase is to ensure that the organic phase is com-
pletely cleared from recombinant RNA that might be
trapped in aggregates or in the residual aqueous layer
from the ﬁrst extraction that could not be harvested
without phenol. The effect of re-extraction is shown in
Figure 3C under DHBVe RNA 15N-labeled, Lane 2.
Additional re-extraction steps yielded no substantial
amounts of RNA. Omitting magnesium acetate from
buffer L results in co-extraction of the majority of the
23S/16S ribosomal RNAs. After HH ribozyme cleavage,
the recombinant RNA still resembles the full-recombinant
RNA molecule through base pairing interactions in the
arms of the construct (Supplementary Figure S3) and is
separated from the small RNA fragments, tRNAs and
5S rRNA, by anion-exchange chromatography on a
ResourceQ 6ml column (Figure 4A, chromatogram).
The small RNAs, tRNAs and 5S rRNA, eluted from
the column at 500mM NaCl, whereas the recombinant
RNA eluted from 525 to 562.5mM NaCl.
Afﬁnity puriﬁcation of the recombinant RNA with
Sephadex G-200 has been employed alternatively to the
phenol-based puriﬁcation. To this extent, the bacterial
cells were disrupted by sonication in a phosphate
binding buffer (buffer SB) containing lysozyme. The
cleared cell lysate was mixed with Sephadex G-200 beads
equilibrated in buffer SB, binding the majority of the re-
combinant RNA as can be observed from Figure 4B, Lane
FT (ﬂow-through). Cellular components as tRNAs,
rRNA, proteins, etc., are washed out with buffer SB
(Figure 4B, Lanes W1–W3), and the bound RNA is then
eluted with buffer SB containing 4 M urea (Figure 4B,
Lanes E1–E7). As can be observed from the Lanes FT
and W1–W3, some leakage of the bound recombinant
RNA from the Sephadex beads occurred during
ﬂowthrough and column washing.
Although small amounts of tRNA and 5S rRNA
co-eluted in the early fractions with the recombinant
RNA during both anion-exchange puriﬁcation of the re-
combinant RNA and, albeit to a lesser extent, the elution
Figure 3. Denaturing 8% polyacrylamide gels of several recombinant RNA transcriptions in E. coli BL21 (DE3) using the employed tRNA-scaffold.
(A) Recombinant Human HBVe RNA production (Figure 1A). RNA content of cells from 1ml of culture at time=1, 2 and 3 h post-induction is
visualized. The produced recombinant RNA is indicated with red arrows, and cellular RNAs and small RNA fragments are indicated with black
arrows. (B) Result of the HH ribozyme cleavage of the dialyzed extract of the recombinant RNA containing the Human HBVe RNA. The scaffold
(S) and the released product (P) are indicated by the red arrows. The red circles indicate the locations of the RNA bands that have disappeared after
HH ribozyme cleavage. (C) Various transcribed RNA sequences at 3 h post-induction (RNA content from 1ml of culture), employing the described
tRNA-scaffold (see Figure 1A and Supplementary Figure S1 for a representation of the fold of the different constructs). The lanes indicated DHBVe
(15N) 1 and 2 show the RNA contents of the ﬁrst extract and the re-extract of 1ml of cells from the 15N-labeled minimal media culture for
production of Duck HBVe RNA, respectively. Bands are visualized with Stains-All (Acros organics, Geel, Belgium).
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of the recombinant RNA from the Sephadex G-200 beads
(Figure 4A, gel Lanes 5 and 6 correspond to Fractions 5
and 6), it was not problematic to distinguish between the
product RNA and the small amount of contaminating
RNAs during excision of the product RNA from prepara-
tive denaturing PAGE, because highly pure product RNA
was obtained in the end (Figure 4C). Lane 1 of Figure 4D
shows a sample of the pooled fractions after anion-
exchange puriﬁcation of the recombinant RNA. As can
be observed, the majority of the degradation fragments,
tRNAs and 5S rRNA, are removed. Lanes 2 and 3 contain
2 and 4 mg, respectively, of the denaturing PAGE-puriﬁed
RNA, showing the absence of admixtures in the isolate.
NMR spectroscopy experiments
Figures 5A–C show the (1H-imino, 15N) HMQC spectra
of the 15N-labeled Duck HBVe RNA, the 15N-labeled
Duck HBVe-mutS1a RNA and the 13C/15N-uridine
labeled Duck HBVe-mutS1a RNA, respectively. The
HMQC spectrum of the recombinant uniformly 15N-
labeled Duck HBVe RNA is conﬁrmed by comparison
with spectra obtained from in vitro produced Duck
HBVe RNA and its fragments (31–35). Resonances as-
signments are based on an imino proton sequential walk
in the (1H,1H) NOESY spectrum combined with the
(1H-imino, 15N) HMQC spectrum and conﬁrmed by com-
parison with the earlier assignments obtained for Duck
HBVe RNA and fragments thereof (31–35). The
(1H-imino, 15N) HMQC spectrum of uniformly 15N-
labeled Duck HBVe-mutS1a RNA (Figure 5B) shows,
despite only a single mutation in the apical loop (U32 to
G32), a signiﬁcant number of new resonances as well as
resonances that have disappeared in comparison with the
Duck HBVe RNA spectrum (Figure 5A). This indicates
Figure 4. Puriﬁcation of recombinant (product) RNAs. (A) FPLC elution proﬁle of the anion-exchange puriﬁcation of phenol extracted and HH
ribozyme cleaved RNA, here shown for unlabeled Duck HBVe-mutL4 RNA. UV absorbance is monitored at 280 nm (red), 260 nm (blue) and 254 nm
(purple); the gradient proﬁle is shown in green. Small RNA fragments, tRNAs and 5S rRNA, elute at 500mM NaCl from the column (Fractions
1–4). The large recombinant RNA construct elutes from 525–562.5mM NaCl (Fractions 5–11). The RNA content of 20 ml of each of the collected
fractions is checked on 8% denaturing PAGE (lane numbers correspond with the collected fractions). (B) Course of the Sephadex G-200 puriﬁcation
of unlabeled Duck HBVe-mutS1a RNA visualized on 8% denaturing PAGE. Twenty microliters of each fraction is loaded onto the gel. FT is the
column ﬂowthrough during settlement of the Sephadex beads. W1, W2 and W3 are the consecutive washing steps with buffer SB to wash out
unbound RNAs. E1–E7 are the elution fractions with buffer SB containing 4M urea. (C) Final purity of the produced NMR samples of the Duck
HBVe RNA, Duck HBVe-mutL4 RNA and Duck HBV-mutS1a RNA, unlabeled and 15N-labeled. Bands are visualized with stains-all. (D) Result of
the anion-exchange column puriﬁcation and denaturing PAGE puriﬁcation. Lane 1 contains 30 mg of recombinant Duck HBVe-mutS1 RNA after
anion-exchange column puriﬁcation. Lanes 2 and 3 contain 2 and 4 mg, respectively, of puriﬁed end product Duck HBVe-mutS1 RNA.
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that the structure of Duck HBVe RNA has changed as a
result of the introduced point mutation in the apical loop
(U32 to G32). In Figure 5C, which shows the (1H-imino,
15N) HMQC spectrum of 13C/15N-uridine labeled Duck
HBVe-mutS1a RNA, the G-imino resonances have
indeed disappeared compared to Figure 5B. The add-
itional resonances in the spectral region between 10 and
12 ppm indicate that additional G:U base pairs are formed
as well as U:U base pairs. The presence of an alternative
structure in Duck HBVe-mutS1a RNA is substantiated by
the Mfold prediction of a shift in base pairings in the
primer binding loop and in the apical loop region
(Supplementary Figure S4a). The G of this structure is
predicted to be 2.2 kcal/mol lower than the structure pre-
dicted for the Duck HBVe RNA. UV melting studies
carried out on Duck HBVe-mutS1a RNA, Duck HBVe
RNA and Duck HBVe-mutL4 RNA (Supplementary
Figure S4b), resulted in melting temperatures of 70, 68
and 68C, respectively, conﬁrming the predicted thermo-
dynamic higher stability of Duck HBVe-mutS1a RNA.
Analysis of the folded state of these Duck HBVe RNAs
assessed by native polyacrylamide gel electrophoresis
(Supplementary Figure S4c) revealed that the Duck
HBVe-mutS1a RNA migrated slightly slower compared
to the Duck HBVe RNA and the Duck HBVe-mutL4
RNA suggesting a more stretched out structure for
Duck HBVe-mutS1a RNA. At present, the NMR and
related biophysical data are further analyzed to fully
establish the nature of the alternate structure.
DISCUSSION
We have shown that several structurally interesting
product RNAs are efﬁciently produced in E. coli BL21
(DE3) using the proposed recombinant RNA production
strategy. These product RNAs are fast and efﬁciently
released from the protective scaffold by the action of the
cis-acting hammerhead ribozymes ﬂanking the product’s
termini. The inexhaustible source of the recombinant
RNA and the employment of common chromatographic
puriﬁcation methods provide a cheap and efﬁcient way of
producing multi-milligram quantities of pure recombinant
product RNAs. The RNAs can be used for experiments
varying from biochemical assays to structural analyses
and drug screenings. We have shown that multi-milligram
amounts of (stable isotope-labeled) RNA sufﬁcient for
NMR structural analyses can be obtained from single
liter bacterial cultures. These recombinant RNAs have
all been obtained within the time frame of one work
week (Supplementary Table S5). Since it is possible to
run productions in parallel, several samples can be
produced simultaneously. Our proposed recombinant
RNA in vivo production system is considerably less time
consuming than enzymatic in vitro transcriptions because
the latter requires additional handlings such as laborious
and costly preparations of linearized plasmid DNA for
in vitro transcriptions and optimization reactions. In
addition, enzymatic in vitro transcriptions are more
costly, because expensive (stable isotope) labeled rNTPs
and large amounts of highly pure T7 RNA polymerase are
needed. Finally, the straightforward bacterial replication
adds another advantage to the in vivo system. Further,
chemical synthesis of (stable isotope labeled) large
RNAs (>50 nt) in high amounts is to date not achievable.
In comparison with other in vivo methods, namely of that
Ponchon et al. (14–16) and Liu et al. (17), our system does
not require stoichiometric amounts of DNA splints to
release the product RNA [RNase H (14–16) or
DNAzyme (17)]. This makes our method somewhat less
time consuming. In addition, no optimization of cleavage
Figure 5. (A) The (1H-imino, 15N) HMQC spectrum of the 15N-labeled
recombinant Duck HBVe RNA. The sequence speciﬁc assignment for
the imino protons was achieved from 2D (1H,1H) NOESY and
(1H-imino,15N) HMQC experiments as described earlier (see the text).
The imino resonances are labeled with their corresponding uridine
residues (resonances between 156 and 164 ppm of the 15N-axis) and
guanosine residues (resonances between 142 and 150 ppm of the
15N-axis) when assigned. One resonance in the spectral region of
imino protons of unpaired or mismatched guanosines remains un-
assigned. (B) The (1H-imino,15N) HMQC spectrum of the 15N-labeled
recombinant Duck HBVe-mutS1a RNA. New appeared imino proton
resonances (9) compared with spectrum (A) are indicated with red
arrows whereas the positions of disappeared imino resonances (2) are
indicated with dashed blue arrows. (C) The (1H-imino,15N) HMQC
spectrum of the selective 13C/15N-uridine labeled in vitro produced
Duck HBVe-mutS1a RNA. The observed imino resonances of the
uridine residues of in vitro produced Duck HBVe-mutS1a RNA corres-
pond with those observed in the recombinant Duck HBVe-mutS1a
RNA.
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reactions is needed and/or recovery of DNA splints. For
instance, the RNase H likely requires tests in advance to
preparative cleavages [e.g. because unspeciﬁc cleavage
may occur (36)]. In contrast, ribozymes, as we use,
are highly speciﬁc and the cleavage initiator Mg2+ is
cheap and can directly be added to the dialyzed RNA
without any prior testing or heat annealing. It should
further be mentioned that in our approach no protein
(e.g. RNAse H) has to be puriﬁed. Finally, the RNAase
H and DNA oligos required ﬁt less optimally with scaling
up of the RNA production. Initially, we attempted to
produce the full-recombinant RNA construct containing
the Human HBVe RNA (Figure 1A) sequence under
the control of the E. coli lpp promoter (14–16). For this
construct, the yield of accumulated recombinant RNA
was very low (results not shown) which was not compat-
ible with our aim to obtain sufﬁcient amounts of RNA for
NMR experiments. We therefore decided to bring the re-
combinant RNA production under the control of T7
RNA polymerase, which is known to display high tran-
scription rates (18,19,37). After IPTG induction in E. coli
BL21 (DE3), efﬁcient and high accumulation of the re-
combinant Human HBVe RNA construct was observed,
and we therefore continued to use this system to obtain
the other presented product RNAs. It should be noted
that the use of T7 RNA polymerase-driven expression
for recombinant RNA synthesis in vivo has been previ-
ously extensively demonstrated by several research
groups for the purpose of a variety functional studies
[see e.g. (8,38,39)], e.g. for the production of large
quantities of aptamer RNA for screening of aptamer
libraries in vivo (8).
The production of the 13 RNAs was very efﬁcient for all
of them (Figure 3, Supplementany Table S3), although for
some the production efﬁciencies were somewhat lower, i.e.
forHIV-1 TARRNAandDuckHBVe-mutS5RNAaswell
as for the long construct containing the GRA RNA.
Optimization of the production may however be of interest
and can be achieved by considering a number of factors.
(i) The lower production yield of the Duck
HBVe-mutS5 RNA is unexpected since the construct
differs only in a predicted structural silent point
mutation from the construct for Duck HBVe-mutS12
RNA (see Supplementary Figure S1, structures J + K)
which produces much better (for unknown reason, the
Sephadex aptamer is predicted to fold differently in
Duck HBV-mutS12). Such differences in production efﬁ-
ciency are also observed between the construct for Duck
HBVe RNA and its predicted structural silent point
mutants Duck HBVe-mutS1a RNA and Duck
HBVe-mutL4 RNA (Supplementary Figure S1, structures
E, F and H). The effect of such small variations in nucleo-
tide composition on the production efﬁciency of the re-
combinant RNA may be exploited to increase the
efﬁciency of constructs that produce moderately.
(ii) The second aspect that appears to affect production
is conformational strain at the junction of the insert
(Figure 1A). The positive effect of a looser fold in this
region is substantiated by the higher production efﬁciency
of the short construct containing the GRA RNA, which
lacks seven base pairing interactions between the scaffold
and the insert compared with the long construct of the
GRA RNA (Figure 1A and 3C).
(iii) Improvements in the yield can potentially also be
achieved by shortening the full-recombinant RNA con-
struct. For the production of recombinant Duck HBVe
RNA and Human HBVe RNA covalently attached to
the tRNAlys-Sephadex aptamer scaffold (15) (i.e. con-
structs without ﬂanking HH ribozymes), we observed
that these RNAs accumulated to signiﬁcantly higher
amounts (Supplementary Figure S5) compared to the
much larger constructs containing HH ribozymes. This
has also been observed by Ponchon and Dardel, and
they suggested that smaller constructs accumulate more
efﬁciently (i.e. to higher number of copies) or are less sus-
ceptible to nuclease degradation. The Sephadex aptamer
might be removed to possibly improve production; puriﬁ-
cation using anion-exchange chromatography is anyhow
faster and yields more product RNA than puriﬁcation
using Sephadex afﬁnity. The 50-TIR could also be
removed as long as two or three guanosine residues
remain to facilitate effective initiation of transcription by
T7 RNA polymerase.
We have tried to further increase the transcription yield
of the recombinant RNAs (without modifying the se-
quences of the full-recombinant RNA constructs) by
transcribing them from the high copy number vector
pUC18 (whereas the pET23b vector is a low copy
number). In our hands, the opposite effect was achieved
and only negligible amounts of recombinant RNA were
produced (results not shown). In addition, lowering the
growth temperature to 30C or 25C, which is common
practice in recombinant protein expression, had no
positive effect on the produced amounts of these and
other recombinant RNAs tested using either pET23b or
pUC18 as the transcription vector.
(iv) We have brieﬂy examined the effect of DNA
templated differences in length of the 50- and 30-termini
of the full-recombinant RNA on the observed band
pattern and yield of a recombinant RNA construct
lacking the Sephadex aptamer and containing a HH
ribozyme ﬂanked Duck HBVe RNA (Supplementary
Figure S6). We observe that the overall band pattern of
the recombinant RNA is identical for all three constructs,
indicating precise recognition and processing of the
tRNA-scaffold moiety by host mechanisms. However,
the yield was signiﬁcantly lower for the construct that
lacks the 50-TIR and contains a long 30-tail of 136 nt
compared to the yield for the construct that lacks both
50-TIR and 30-tail and the construct that contains the
50-TIR and lacks a 30-tail; the latter constructs were in
turn comparable in yield.
In all cases for which we demonstrated the fast RNA
production using the HH-tRNA scaffold, the product
RNAs terminate in a closing stem. The sequences at the
termini of these stems are 50-GAC and GUC-30 and
are designed to be compatible with the UX (X 6¼G)
sequence requirements of the HH ribozyme preceding 50
to the cleavage site at the 30-terminus of the product RNA
(40–42). If desired, the sequence restrictions at the
30-terminus can be overcome by placing the hepatitis d
virus ribozyme or the hairpin ribozyme (43,44) at this
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position instead. The 50-terminus of the product RNA is
not impeded by sequence restrictions of the HH ribozyme
and can be tailored to ones wishes.
During the time of recombinant RNA production in E.
coli BL21 (DE3), the HH ribozymes are already cleaved to
some extent because of the presence of Mg2+(and/or other
divalent metal ions catalyzing cleavage, such as Mn2+and
Ca2+) in the growth medium. However, we can conclude
from native gel experiments (Supplementary Figure S3)
that the ‘product RNA’ does not (fully or partially) dis-
sociate from the scaffold at room temperature after
HH-ribozyme cleavage and thus also not during the
in-cell HH-ribozyme cleavage. DINAmelt (23) simulations
conﬁrm that the integrity of the recombinant RNA is
maintained and results from the highly complementary
sequence of the product RNA and scaffold arms.
Furthermore, note that short RNA degradation fragments
are observed during all recombinant RNA productions.
These short RNA degradation fragments are also seen in
productions of recombinant RNAs without ﬂanking ham-
merhead ribozymes (Supplementary Figure S5) as well as
in productions with an inactive ribozyme, as employed in
the construct for Human HBVe RNA (results not shown).
These short RNA degradation fragments probably origin-
ate from the processed recombinant RNA and are efﬁ-
ciently removed by both proposed puriﬁcation methods
and do not contaminate the end-product RNA. Thus, it
appears that although cleavage takes place, the recombin-
ant RNA (scaffold and product RNA) stays intact in the
cell. This also implies that the Mg2+-activated
HH-ribozyme cleavage does not hamper up-scaling of
the RNA production. On the other hand, if for some
reason in-cell cleavage is undesired, e.g. that apart from
the product RNA also the full-recombinant RNA is
required, the constructs can potentially be equipped with
allosterically regulated ribozymes (45). This allows
cleavage to be initiated only upon the addition of the
ligand that induces the required conformational change
to activate the ribozyme, provided that this ligand is not
naturally occurring in E. coli. These ligands are often
readily available small molecules, so that scaling up of
the production appears straightforward. The proposed
method is demonstrated here on product RNAs in the
range of 55–70 nt in length. Production and puriﬁcation
of product RNAs in the range of 70–200 nt is possible with
the same methodology. Note, however, that care should
be taken in the design of the full-recombinant RNA
molecule that the sizes of product RNA and scaffold
moieties are such that their bands do not overlap on the
denaturing gel during separation (e.g. tailor the length of
the scaffold arms).
After ribozyme cleavage, the product RNA contains a
50-hydroxyl and a 203 0-cyclic phosphodiester at its termini.
These groups are protected against ligation catalyzed by
nucleic acid ligases. This opens the route for cost-efﬁcient
segmental stable isotope labeling by cross ligation of RNA
segments obtained by site-speciﬁc RNase H digestion
(36,46). The segments can either be puriﬁed using prepara-
tive denaturing PAGE or using denaturing anion-
exchange HPLC/FPLC (14–16,36). Ligation can be
performed via DNA splinted ligation using T4 DNA
ligase (25,36,47) or via hybridization of the individual
RNA segments and T4 RNA ligase type 1 or 2
(25,36,48–50).
In the protocol by Ponchon and Dardel for recombin-
ant RNA production, freshly transformed bacterial cells
and a strict growth protocol are required to avoid possible
formation of mutations in the RNA (14,15). By using our
method, the cells can be stored in glycerol at 80C and
cultivation can be initiated by inoculation from this stock
or, alternatively, from plate/small cultures. The recombin-
ant RNA does not have to accumulate during overnight
growth, but the plateau is generally reached 3 h post-in-
duction, which makes the production less time consuming.
It should be mentioned that the employed T7 system is
prone to basal transcription during bacterial growth in the
absence of the inducer (IPTG). If the transcribed recom-
binant RNA is detrimental to the host, the gene coding for
the recombinant RNA might be lost or inactivated. In the
case of problems (e.g. mutations or gene loss) with recom-
binant RNA productions, E. coli Bl21 (DE3) strains ex-
pressing T7 lysozyme (e.g. from the plasmids pLysS or
pLysE) (51) or attenuation of basal T7 RNA polymerase
expression (52) might be used to restrict basal transcrip-
tion and the possible acquisition of mutations. Thus far,
we have not encountered such production failures with the
employed system, but this might occur in productions for
other RNA constructs in which case the above suggested
work around may form a viable option.
Furthermore, with the presented RNA production
system, perdeuterated recombinant RNA can potentially
be produced by exchanging the growth medium with D2O
(53–55) and/or site-speciﬁc labeling patterns can be
introduced in the nucleotides (55–57). Additionally, the
scaffold RNA, 5S rRNA and tRNAs (and also the 23S/
16S rRNA where Sephadex G-200 is used), can be
co-puriﬁed during puriﬁcation of the product RNA.
These RNAs contain the same labeling pattern as the
product RNA and can be enzymatically digested into
rNMPs. Phosphorylation of the rNMPs into their corres-
ponding rNTPs (58) makes them useful for the production
of labeled RNA transcribed in vitro (1) or, after conver-
sion into their corresponding dNTPs, for the production
of labeled DNA (59–62).
Scalability of RNA production and puriﬁcation
The described protocol for laboratory scale puriﬁcation of
the full-recombinant RNA and also of the product RNAs
from the scaffold RNA involves production of milligram
quantities (corresponding to 1 l cultures). We routinely
purify (stable isotope labeled) nucleic acids for NMR
structural analysis via this protocol, which employs
large-scale (preparative) PAGE puriﬁcation. We ﬁnd
that it is reliable, relatively fast and reproducible. In
addition, it has high resolution (1 nt) and leads to highly
pure RNAs. Scaling up of the production up to 10 l
appears doable with this PAGE puriﬁcation.
Alternatively, for the separation of the product RNA
from the scaffold RNA moieties, more specialized equip-
ment can be used such as preparative denaturing PAGE
cells (Bio-Rad).
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Beyond the 10 l scale, other puriﬁcation methods should
be considered. Potentially, alternate methods such as e.g.
denaturing reversed phase HPLC or FPLC or denaturing
anion-exchange HPLC or FPLC may then be employed,
although they may also be applicable at the laboratory
scale. However, these column methods may suffer from
lower resolution. It depends on the application whether
the ﬁnal-product RNA needs to be highly pure. For re-
combinant RNA productions and puriﬁcations beyond
laboratory scale, more development is clearly required.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–5, Supplementary Figures 1–6.
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